Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy

Journal of Clinical Virology

Volumn 51, Issue 4, 2011, Pages 241-245

  Kim, Yeo Myeong ^a   Jeong, Sook Hyang ^a   Kim, Jin Wook ^a   Lee, Sang Hyub ^a   Hwang, Jin Hyuk ^a   Park, Young Soo ^a   Kim, Nayoung ^a   Lee, Jong Seok ^a   Kim, Hyun Young ^a   Lee, Dong Ho ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Hepatitis B virus; Non Hodgkin's lymphoma; Prophylactic therapy; Reactivation; Systemic chemotherapy

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 79960059322     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.05.004     Document Type: Article

References (29)

1. Nath A., Agarwal R., Malhotra P., Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin's lymphoma. A systematic review and meta-analysis. Intern Med J 2010, 40:633-641.
2. Engels E.A., Cho E.R., Jee S.H. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010, 11:827-834.
3. Marcucci F., Mele A., Spada E., Candido A., Bianco E., Pulsoni A., et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006, 91:554-557.
4. Kim J.H., Bang Y.J., Park B.J., Yoo T., Kim C.W., Kim T.Y., et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 2002, 93:471-477.
5. Park S.C., Jeong S.H., Kim J., Han C.J., Kim Y.C., Choi K.S., et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. J Med Virol 2008, 80:960-966.
6. Anderson L.A., Pfeiffer R., Warren J.L., Landgren O., Gadalla S., Berndt S.I., et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008, 17:3069-3075.
7. Sonmez M., Bektas O., Yilmaz M., Durmus A., Akdogan E., Topbas M., et al. The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. Tumori 2007, 93:536-539.
8. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49:S156-S165.
9. Kwag J.Y., Jung S.H., Kang Y.K., Han C.J., Kim Y.C., Lee J.O., et al. Acute exacerbation of hepatitis in hepatitis B virus carriers with non-Hodgkin's lymphoma after chemotherapy Korean. J Gastroenterol 2000, 35:64-72.
10. Ku B.K., Hahn J.S., Hahn K.H., Lee S.T., Suh H.C., Kwon K.H., et al. Clinical outcome of the HBsAg positive malignant lymphoma patients following anticancer chemotherapy. Korean J Med 1997, 52:542-549.
11. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699-712.
12. Lau G.K. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008, 2:152-162.
13. Ziakas P.D., Karsaliakos P., Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 94:998-1005.
14. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
15. Artz A.S., Somerfield M.R., Feld J.J., Giusti A.F., Kramer B.S., Sabichi A.L., et al. American society of clinical oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010, 28:3199-3202.
16. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
17. Hsu C., Hsiung C.A., Su I.J., Hwang W.S., Wang M.C., Lin S.F., et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853.
18. Ulcickas Yood M., Quesenberry C.P., Guo D., Caldwell C., Wells K., Shan J., et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007, 46:107-112.
19. Kang J., Cho J.H., Suh C.W., Lee D.H., Oh H.B., Sohn Y.H., et al. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol 2010, 90:159-164.
20. Pontisso P., Morsica G., Ruvoletto M.G., Zambello R., Colletta C., Chemello L., et al. Hepatitis B virus binds to peripheral blood mononuclear cells via the pre S1 protein. J Hepatol 1991, 12:203-206.
21. Murakami Y., Minami M., Daimon Y., Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004, 72:203-214.
22. Umeda M., Marusawa H., Seno H., Katsurada A., Nabeshima M., Egawa H., et al. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol 2005, 42:806-812.
23. Stoll-Becker S., Repp R., Glebe D., Schaefer S., Kreuder J., Kann M., et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol 1997, 71:5399-5407.
24. Pontisso P., Vidalino L., Quarta S., Gatta A. Biological and clinical implications of HBV infection in peripheral blood mononuclear cells. Autoimmun Rev 2008, 8:13-17.
25. Dai M.S., Chao T.Y., Kao W.Y., Shyu R.Y., Liu T.M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004, 83:769-774.
26. Hui C.K., Cheung W.W., Au W.Y., Lie A.K., Zhang H.Y., Yueng Y.H., et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005, 54:1597-1603.
27. Lee K.S., Kim D.J. Management of chronic hepatitis B. Korean J Hepatol 2007, 13:447-488.
28. European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
29. Lok A.S., McMahon B.J. Chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-861.